文献速递心脑血管急症

瑞替普酶与阿替普酶治疗急性缺血性卒中比较

Reteplase versus Alteplase for Acute Ischemic Stroke.
PubMed 文献 · N Engl J Med · 2024-06-14
一句话结论症状发作4.5小时内急性缺血性卒中患者,静脉瑞替普酶(18 mg两次弹丸注射)90天极佳功能结局优于阿替普酶(0.9 mg/kg,最大90 mg)。

RAISE试验将症状发作4.5小时内的急性缺血性卒中患者1:1随机分配接受静脉瑞替普酶(18 mg弹丸注射,30分钟后第二次18 mg弹丸注射)或静脉阿替普酶(0.9 mg/kg,最大剂量90 mg)。主要疗效终点90天极佳功能结局(改良Rankin量表评分0或1分)在瑞替普酶组为79.5%,阿替普酶组为70.4%(风险比1.13;95%CI 1.05~1.21;非劣效性P<0.001,优效性P=0.002)。症状性颅内出血36小时内发生率两组分别为2.4%和2.0%(风险比1.21;95%CI 0.54~2.75),90天任何颅内出血发生率瑞替普酶组高于阿替普酶组(7.7% vs 4.9%;风险比1.59;95%CI 1.00~2.51),不良事件发生率亦更高(91.6% vs 82.4%;风险比1.11;95%CI 1.03~1.20)。

要点

  • 症状发作4.5小时内急性缺血性卒中,瑞替普酶组90天极佳功能结局79.5%,阿替普酶组70.4%(风险比1.13;95%CI 1.05~1.21;优效性P=0.002)。
  • 瑞替普酶给药方案:18 mg静脉弹丸注射,30分钟后第二次18 mg弹丸注射;阿替普酶0.9 mg/kg静脉给药,最大剂量90 mg。
  • 36小时内症状性颅内出血瑞替普酶组2.4%(17/700),阿替普酶组2.0%(14/699),风险比1.21(95%CI 0.54~2.75)。
  • 90天任何颅内出血瑞替普酶组7.7%,阿替普酶组4.9%(风险比1.59;95%CI 1.00~2.51);不良事件发生率91.6% vs 82.4%(风险比1.11;95%CI 1.03~1.20)。

适用人群与场景

  • 症状发作4.5小时内的急性缺血性卒中患者,随机分组接受静脉溶栓治疗。

诊断标准与关键阈值

  • 主要疗效终点:90天改良Rankin量表评分0或1分(极佳功能结局);量表范围0分(无神经功能缺损、无症状或完全恢复)至6分(死亡)。
  • 主要安全终点:症状发作36小时内的症状性颅内出血。

处置流程与药物剂量

  • 瑞替普酶组:静脉弹丸注射18 mg,30分钟后第二次静脉弹丸注射18 mg。
  • 阿替普酶组:静脉给药0.9 mg/kg体重,最大剂量90 mg。

研究设计与关键结果

  • 多中心随机对照试验(RAISE,NCT05295173),共纳入1412例患者,瑞替普酶组707例,阿替普酶组705例。
  • 90天极佳功能结局:瑞替普酶组79.5%,阿替普酶组70.4%(风险比1.13;95%CI 1.05~1.21;非劣效性P<0.001,优效性P=0.002)。
  • 36小时内症状性颅内出血:瑞替普酶组17/700(2.4%),阿替普酶组14/699(2.0%)(风险比1.21;95%CI 0.54~2.75)。
  • 90天任何颅内出血:瑞替普酶组7.7%,阿替普酶组4.9%(风险比1.59;95%CI 1.00~2.51)。
  • 不良事件:瑞替普酶组91.6%,阿替普酶组82.4%(风险比1.11;95%CI 1.03~1.20)。

证据类型、等级与局限

  • 证据类型:随机对照试验(RAISE)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在症状发作4.5小时内的缺血性卒中患者中,瑞替普酶较阿替普酶更可能获得极佳功能结局。

指南或共识出处

  • RAISE试验,ClinicalTrials.gov注册号NCT05295173,由China Resources Angde Biotech Pharma等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with acute ischemic stroke are unclear.

METHODS: We randomly assigned patients with ischemic stroke within 4.5 hours after symptom onset in a 1:1 ratio to receive intravenous reteplase (a bolus of 18 mg followed 30 minutes later by a second bolus of 18 mg) or intravenous alteplase (0.9 mg per kilogram of body weight; maximum dose, 90 mg). The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no neurologic deficit, no symptoms, or completely recovered] to 6 [death]) at 90 days. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after symptom onset.

RESULTS: A total of 707 patients were assigned to receive reteplase, and 705 were assigned to receive alteplase. An excellent functional outcome occurred in 79.5% of the patients in the reteplase group and in 70.4% of those in the alteplase group (risk ratio, 1.13; 95% confidence interval [CI], 1.05 to 1.21; P<0.001 for noninferiority and P = 0.002 for superiority). Symptomatic intracranial hemorrhage within 36 hours after disease onset was observed in 17 of 700 patients (2.4%) in the reteplase group and in 14 of 699 (2.0%) of those in the alteplase group (risk ratio, 1.21; 95% CI, 0.54 to 2.75). The incidence of any intracranial hemorrhage at 90 days was higher with reteplase than with alteplase (7.7% vs. 4.9%; risk ratio, 1.59; 95% CI, 1.00 to 2.51), as was the incidence of adverse events (91.6% vs. 82.4%; risk ratio, 1.11; 95% CI, 1.03 to 1.20).

CONCLUSIONS: Among patients with ischemic stroke within 4.5 hours after symptom onset, reteplase was more likely to result in an excellent functional outcome than alteplase. (Funded by China Resources Angde Biotech Pharma and others; RAISE ClinicalTrials.gov number, NCT05295173.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Li S, Gu HQ, Li H, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med. 2024. PMID: 38884332. doi:10.1056/NEJMoa2400314

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。